Received Feb 20, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | UNK | — | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | UNK | — | — |
has not yet received their third dose; No additional AE; This spontaneous report was received from a Pharmacist and refers to a 25-year-old male patient. The patient's medical, concurrent conditions, previous drugs reactions or allergies and concomitant therapies were not reported. On an unknown date in April 2023, the patient started therapy with Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL®9), (Dose 1) (strength, dose description, route of administration, lot # and expiration date were not reported). On an unknown date in June 2023, the patient was vaccinated with Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL®9) (GARDASIL®9), (dose 2) (strength, dose description, route of administration, lot # and expiration date were not reported) as prophylaxis, however, the patient has not yet received their third dose (Inappropriate schedule of product administration). No symptoms reported, No additional adverse event.